Ipamorelin Research Guide: Selectivity, Potential Benefits and Evidence

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide studied as a growth hormone secretagogue and ghrelin mimetic. Researchers have investigated its endocrine pharmacology and gastrointestinal effects. QRP Research supplies a 5 mg research vial; this guide separates the published findings from claims that go beyond those findings.

Potential benefits: selective GH signalling

The foundational pharmacology study examined pituitary cells, rats and swine. Ipamorelin stimulated GH release, and the swine experiments found less accompanying ACTH and cortisol stimulation than with certain comparator secretagogues. These findings explain scientific interest in selectivity. They do not mean that ipamorelin has no side effects or that the same selectivity guarantees a clinical benefit in humans. Read the original 1998 study.

Gastrointestinal research in people

Ipamorelin has also been investigated after bowel resection, where postoperative ileus can delay gastrointestinal recovery. A randomised proof-of-concept trial reported no significant differences from placebo in its key and secondary efficacy analyses. This negative result belongs alongside the promising mechanism: it prevents a general claim that ipamorelin is proven to restore gut function. Read the clinical trial.

What about muscle, recovery and sleep?

The studies discussed here do not establish reliable improvements in muscle growth, exercise recovery, fat loss or sleep. GH release is a biological response, not a substitute for measuring those outcomes directly. A claim about a combination with another secretagogue also needs evidence for the actual combination; it cannot be established simply by combining findings from separate studies.

Safety cannot be inferred from selectivity

FDA's safety review highlights potential immune reactions and peptide impurities. It also notes serious events, including death, reported during an intravenous gastrointestinal study, and insufficient information for certain other injectable routes. A reported event does not by itself prove causation, but these data do not support a blanket safety claim.

Reading the 5 mg label and batch report

The labelled mass identifies the product presentation; it is not a usage protocol. For research planning, confirm the lot number, molecular identity and test methods in the current Certificate of Analysis. A high chromatographic purity figure does not independently verify sterility, biological activity or suitability for administration. Laboratory preparation and storage should follow the validated requirements of the intended experiment.

QRP product and sources

View QRP Research Ipamorelin 5 mg for current product and batch details. The linked primary studies let readers distinguish animal pharmacology from human clinical evidence. QRP material is for laboratory research only and is not supplied for human or veterinary administration.